The National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio a second SBIR Phase I to apply the GlycoSenseTM technology to monitoring glycoenzyme engineering reactions.
Lectenz Bio receives NIH SBIR Phase I
Category: Lectenz Bio News
Date: September 1, 2017
Author: lectenz® Bio